Johnson & Johnson (NYSE:JNJ) Receives Coverage Optimism Score of -3.40

News coverage about Johnson & Johnson (NYSE:JNJ) has trended very negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Johnson & Johnson earned a coverage optimism score of -3.40 on their scale. InfoTrie also gave news headlines about the company an news buzz score of 0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news articles that may have impacted Johnson & Johnson’s ranking:

NYSE:JNJ opened at $129.90 on Thursday. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The business’s 50-day moving average price is $130.50 and its two-hundred day moving average price is $134.53. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $337.87 billion, a price-to-earnings ratio of 15.88, a PEG ratio of 2.16 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.54% and a net margin of 21.09%. The firm had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. During the same quarter in the prior year, the firm posted $2.05 earnings per share. The company’s quarterly revenue was up 1.9% on a year-over-year basis. Sell-side analysts predict that Johnson & Johnson will post 8.65 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 2.93%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s payout ratio is 46.45%.

Several equities analysts have recently issued reports on JNJ shares. Credit Suisse Group upped their price target on Johnson & Johnson from $156.00 to $158.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Raymond James cut their price target on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Wells Fargo & Co cut their price target on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 16th. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target on the stock in a research note on Friday, October 11th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $151.18.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: How can investors find ex-dividend dates?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.